The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity
Open accessAbstract
SUMMARY While mutations in DNA are the best-studied source of neoantigens that determine response to immune checkpoint blockade, alterations in RNA splicing within cancer cells could similarly result in neoepitope production. However, the endogenous antigenicity and clinical potential of such splicing-derived epitopes have not been tested. Here, we demonstrate that pharmacologic modulation of splicing via specific drug classes generates bona fide neoantigens and elicits anti-tumor immunity, augmenting checkpoint immunotherapy. Splicing modulation inhibited tumor growth and enhanced checkpoint blockade in a manner dependent on host T cells and peptides presented on tumor MHC class I. Splicing modulation induced stereotyped splicing changes across tumor types, altering the MHC I-bound immunopeptidome to yield splicing-derived neoepitopes which trigger an anti-tumor T cell response in vivo. These data definitively identify splicing modulation as an untapped source of immunogenic peptides and provide a means to enhance response to checkpoint blockade that is readily translatable to the clinic. In Brief sentence: By provoking production of “neoantigens” that are recognized by immune cells, drugs that modulate RNA splicing can enhance cancer immunotherapy. Original, unedited In Brief (do not use): Here, we present definitive proof of concept that pharmacologic modulation of RNA splicing enhances anti-tumor immunity via the generation of endogenous, mis-spliced antigenic peptides and augments the efficacy of immune checkpoint blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G., Hayes, A., Henry, L., Hester, J., et al. (2019) · Journal of Open Source Software · doi:10.21105/joss.01686 · Cited by 22,138
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
TopHat: discovering splice junctions with RNA-Seq
Trapnell, C., Pachter, L., & Salzberg, S. L. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp120 · Cited by 11,617
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationDose-Response Analysis Using R
Ritz, C., Baty, F., Streibig, J. C., & Gerhard, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0146021 · Cited by 3,658
Orchestrating high-throughput genomic analysis with Bioconductor
Huber, W., Carey, V. J., Gentleman, R., Anders, S., Carlson, M., Carvalho, B. S., Bravo, H. C., Davis, S., Gatto, L., Girke, T., et al. (2015) · Nature Methods · doi:10.1038/nmeth.3252 · Cited by 3,608
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552 · cited 2×
“Therapeutic benefit is associated with increased mutational burden (Marabelle et al., 2020; Sha et al., 2020) and mismatch repair deficiency (Le et al.”
Jurtz, V., Paul, S., Andreatta, M., Marcatili, P., Peters, B., & Nielsen, M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700893 · Cited by 1,470
Analysis and design of RNA sequencing experiments for identifying isoform regulation
Katz, Y., Wang, E. T., Airoldi, E. M., & Burge, C. B. (2010) · Nature Methods · doi:10.1038/nmeth.1528 · Cited by 1,353
Self-citationPredicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
Hutchinson, J. N., Ensminger, A. W., Clemson, C. M., Lynch, C. R., Lawrence, J. B., & Chess, A. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-39 · Cited by 996
The UCSC Genome Browser database: extensions and updates 2013
Meyer, L. R., Zweig, A. S., Hinrichs, A. S., Karolchik, D., Kuhn, R. M., Wong, M., Sloan, C. A., Rosenbloom, K. R., Roe, G., Rhead, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1048 · Cited by 900
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients
Kahles, A., Lehmann, K.-V., Toussaint, N. C., Hüser, M., Stark, S. G., Sachsenberg, T., Stegle, O., Kohlbacher, O., Sander, C., Caesar-Johnson, S. J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.001 · Cited by 897
Self-citationFlicek, P., Ahmed, I., Amode, M. R., Barrell, D., Beal, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., Fairley, S., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1236 · Cited by 869
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
Sha, D., Jin, Z., Budczies, J., Kluck, K., Stenzinger, A., & Sinicrope, F. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0522 · Cited by 859
Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D. (2017) · Science · doi:10.1126/science.aal3755 · Cited by 762
Bayesian hypothesis testing for psychologists: A tutorial on the Savage–Dickey method
Wagenmakers, E.-J., Lodewyckx, T., Kuriyal, H., & Grasman, R. (2010) · Cognitive Psychology · doi:10.1016/j.cogpsych.2009.12.001 · Cited by 740
RNA splicing factors as oncoproteins and tumour suppressors
Dvinge, H., Kim, E., Abdel-Wahab, O., & Bradley, R. K. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.51 · Cited by 687
Self-citationAbelin, J. G., Keskin, D. B., Sarkizova, S., Hartigan, C. R., Zhang, W., Sidney, J., Stevens, J., Lane, W., Zhang, G. L., Eisenhaure, T. M., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.007 · Cited by 617
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
Chan-Penebre, E., Kuplast, K. G., Majer, C. R., Boriack-Sjodin, P. A., Wigle, T. J., Johnston, L. D., Rioux, N., Munchhof, M. J., Jin, L., Jacques, S. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1810 · Cited by 569
Wells, D. K., van Buuren, M. M., Dang, K. K., Hubbard-Lucey, V. M., Sheehan, K. C. F., Campbell, K. M., Lamb, A., Ward, J. P., Sidney, J., Blazquez, A. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.015 · Cited by 538
Self-citationThe protein Aly links pre-messenger-RNA splicing to nuclear export in metazoans
Zhou, Z., Luo, M.-J., Straesser, K., Katahira, J., Hurt, E., & Reed, R. (2000) · Nature · doi:10.1038/35030160 · Cited by 517
Seiler, M., Yoshimi, A., Darman, R., Chan, B., Keaney, G., Thomas, M., Agrawal, A. A., Caleb, B., Csibi, A., Sean, E., et al. (2018) · Nature Medicine · doi:10.1038/nm.4493 · Cited by 507
Self-citationMHCflurry: Open-Source Class I MHC Binding Affinity Prediction
O'Donnell, T. J., Rubinsteyn, A., Bonsack, M., Riemer, A. B., Laserson, U., & Hammerbacher, J. (2018) · Cell Systems · doi:10.1016/j.cels.2018.05.014 · Cited by 409
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Bertrand, F., Montfort, A., Marcheteau, E., Imbert, C., Gilhodes, J., Filleron, T., Rochaix, P., Andrieu-Abadie, N., Levade, T., Meyer, N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02358-7 · Cited by 384
Lee, S. C.-W., Dvinge, H., Kim, E., Cho, H., Micol, J.-B., Chung, Y. R., Durham, B. H., Yoshimi, A., Kim, Y. J., Thomas, M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4097 · Cited by 347
Self-citationFedoriw, A., Rajapurkar, S. R., O'Brien, S., Gerhart, S. V., Mitchell, L. H., Adams, N. D., Rioux, N., Lingaraj, T., Ribich, S. A., Pappalardi, M. B., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.014 · Cited by 339
Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia
Wang, E., Lu, S. X., Pastore, A., Chen, X., Imig, J., Chun-Wei Lee, S., Hockemeyer, K., Ghebrechristos, Y. E., Yoshimi, A., Inoue, D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.010 · Cited by 338
Self-citationIntron retention is a source of neoepitopes in cancer
Smart, A. C., Margolis, C. A., Pimentel, H., He, M. X., Miao, D., Adeegbe, D., Fugmann, T., Wong, K.-K., & Van Allen, E. M. (2018) · Nature Biotechnology · doi:10.1038/nbt.4239 · Cited by 322
A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases
Eram, M. S., Shen, Y., Szewczyk, M. M., Wu, H., Senisterra, G., Li, F., Butler, K. V., Kaniskan, H. Ü., Speed, B. A., dela Seña, C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00839 · Cited by 289
Self-citationIshihama, Y., Rappsilber, J., & Mann, M. (2006) · Journal of Proteome Research · doi:10.1021/pr050385q · Cited by 284
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation
Fong, J. Y., Pignata, L., Goy, P.-A., Kawabata, K. C., Lee, S. C.-W., Koh, C. M., Musiani, D., Massignani, E., Kotini, A. G., Penson, A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.07.003 · Cited by 270
Self-citationSystematic Analysis of Splice-Site-Creating Mutations in Cancer
Jayasinghe, R. G., Cao, S., Gao, Q., Wendl, M. C., Vo, N. S., Reynolds, S. M., Zhao, Y., Climente-González, H., Chai, S., Wang, F., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.052 · Cited by 239
Self-citationBiological validation that SF3b is a target of the antitumor macrolide pladienolide
Yokoi, A., Kotake, Y., Takahashi, K., Kadowaki, T., Matsumoto, Y., Minoshima, Y., Sugi, N. H., Sagane, K., Hamaguchi, M., Iwata, M., et al. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08387.x · Cited by 177
Proteomics profiling of arginine methylation defines PRMT5 substrate specificity
Musiani, D., Bok, J., Massignani, E., Wu, L., Tabaglio, T., Ippolito, M. R., Cuomo, A., Ozbek, U., Zorgati, H., Ghoshdastider, U., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aat8388 · Cited by 170
Lesterhuis, W. J., Salmons, J., Nowak, A. K., Rozali, E. N., Khong, A., Dick, I. M., Harken, J. A., Robinson, B. W. S., & Lake, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061895 · Cited by 152
Hubert, C. G., Bradley, R. K., Ding, Y., Toledo, C. M., Herman, J., Skutt-Kakaria, K., Girard, E. J., Davison, J., Berndt, J. D., Corrin, P. D., et al. (2013) · Genes & Development · doi:10.1101/gad.212548.112 · Cited by 145
Self-citationThomas, J. D., Polaski, J. T., Feng, Q., Neef, E. D., Hoppe, E. R., McSharry, M. V., Pangallo, J., Gabel, A. M., Belleville, A. E., Watson, J., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0555-z · Cited by 141
Self-citationBruijn, M. L. H. D., Schumacher, T. N., Nieland, J. D., Ploegh, H. L., Kast, W. M., & Melief, C. J. M. (1991) · European Journal of Immunology · doi:10.1002/eji.1830211210 · Cited by 93
Sample processing obscures cancer-specific alterations in leukemic transcriptomes
Dvinge, H., Ries, R. E., Ilagan, J. O., Stirewalt, D. L., Meshinchi, S., & Bradley, R. K. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413374111 · Cited by 83
Self-citationA tissue-based draft map of the murine MHC class I immunopeptidome
Schuster, H., Shao, W., Weiß, T., Pedrioli, P. G. A., Roth, P., Weller, M., Campbell, D. S., Deutsch, E. W., Moritz, R. L., Planz, O., et al. (2018) · Scientific Data · doi:10.1038/sdata.2018.157 · Cited by 63
Silva, A. D. D., Boesteanu, A. C., Song, R., Nagy, N., Harhaj, E. W., Harding, C. V., & Joyce, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.8.4413 · Cited by 58
Murphy, J. P., Konda, P., Kowalewski, D. J., Schuster, H., Clements, D. R., Kim, Y., Cohen, A., Sharif, T., Nielsen, M., Stevanović, S., et al. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00971 · Cited by 45
Ross, P., Holmes, J. C., Gojanovich, G. S., & Hess, P. R. (2012) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2012.08.012 · Cited by 25
Cited by
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
Exploiting senescence for the treatment of cancer
Wang, L., Lankhorst, L., & Bernards, R. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00450-9 · Cited by 867
RNA splicing dysregulation and the hallmarks of cancer
Bradley, R. K., & Anczuków, O. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00541-7 · Cited by 579
Self-citationRational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Arginine reprograms metabolism in liver cancer via RBM39
Mossmann, D., Müller, C., Park, S., Ryback, B., Colombi, M., Ritter, N., Weißenberger, D., Dazert, E., Coto-Llerena, M., Nuciforo, S., et al. (2023) · Cell · doi:10.1016/j.cell.2023.09.011 · Cited by 293
Metadata
- Authors
- Lu, S. X., De Neef, E., Thomas, J. D., Sabio, E., Rousseau, B., Gigoux, M., Knorr, D. A., Greenbaum, B., Elhanati, Y., Hogg, S. J., Chow, A., Ghosh, A., Xie, A., Zamarin, D., Cui, D., Erickson, C., Singer, M., Cho, H., Wang, E., Lu, B., Durham, B. H., Shah, H., Chowell, D., Gabel, A. M., Shen, Y., Liu, J., Jin, J., Rhodes, M. C., Taylor, R. E., Molina, H., Wolchok, J. D., Merghoub, T., Diaz, L. A., Abdel-Wahab, O., & Bradley, R. K.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 184
- Issue
- 15
- Pages
- 4032-4047.e31
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W3176618876
- Cited by
- 284
- References
- 47
- FWCI
- 15.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.